Dexmedetomidine on Brain Injury Patients

• Approval will be obtained from the Research Ethics Committee of Faculty of Pharmacy, Damanhour University.
• All participants must agree to take part in this clinical study and provide informed consent.
• The required sample size will be calculated.
• 60 Patients with brain injury will be enrolled from the intensive care department, Damanhour medical national institute.
• Serum samples will be collected for measuring the biomarkers.
• All enrolled 60 patients will be mentioned as two groups; Group 1(n=30): are the patients who will receive dexmedetomidine. Group 2 (n=30): are the patients who represent the control group.
• All patients will be followed up during their stay in the intensive care department.
• During their stay in the intensive care department, step 5 will be repeated.
• Statistical tests appropriate to the study design will be conducted to evaluate the significance of the results.
• Measuring outcomes: the primary outcome is measuring the neuroprotection provided by dexmedetomidine reflected by change in patients' symptoms, while secondary outcome is the change in the level of biomarkers from baseline to post-treatment.
• Results, discussion, conclusion, and recommendations will be given.

Inclusion criteria

• 60 Patients with brain injury with age ranging from 18 to 70 years, there are no limits to gender.

Exclusion criteria

• Patients with significant liver impairment
• Patients with known heart failure
• Patients with hypotension
• Patients with bradycardia